(‘NetScientific’ or ‘the Group’)
NetScientific Invests in Next Generation, Immunotherapeutics Company,
15 December 2014: NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announced it has made an investment in PDS Biotechnology Corporation (‘PDS’).
PDS is a clinical stage immunotherapy company developing a next-generation of simpler, safer and more effective immunotherapies for cancer and infectious disease. Its novel synthetic nanoparticle platform technology developed by PDS, Versamune®, activates multiple immunological mechanisms which direct the targeting of cancer and infectious disease by the immune system.
The Company’s lead product, PDS0101, is in phase I clinical trials in the US for HPV-related cancers. PDS has licensed the Versamune® technology to Merck KGaA for use in two early stage cancer immunotherapy programmes. The company has also ongoing pre-clinical programmes for other cancers as well as pandemic influenza.
Farad Azima, CEO, “This is an exceptional opportunity for NetScientific. As we stated in our recent results, we have been evaluating opportunities in the therapeutic space. PDS Biotechnology is at the forefront of cancer immunotherapies and by investing in the company, represents our entry into next generation therapeutics.”
Sir Richard Sykes, Chairman added, “The groundbreaking work of PDS in developing immunotherapeutics has the potential to transform treatments for a wide range of cancers and infectious diseases. We are delighted to be supporting the Company through its next stage of development.”
Notes to Editors
NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people’s lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.NetScientific.net
PDS Biotechnology is an immunotherapeutics company developing its powerful nanoparticle technology, called Versamune®, as a novel cancer therapy platform with outstanding potential in directing the immune system to recognise and fight disease. The Company is developing a range of applications in cancer and infectious disease and its first lead compound is in phase I clinical trials. The company is based in New Jersey, US. For specific information on PDS please contact Michael King at email@example.com. http://www.pdsbiotech.com
Tel: +44 (0) 20 3290 8877
Liberum (NOMAD and Broker)
Chris Bowman / Christopher Britton /
Tel: +44 (0)20 3100 2000
Melanie Toyne-Sewell / Tim Watson
Tel: +44 (0) 20 7457 2020